Document is current
Any future updates will be listed below
-
Authors
Zhang, Chao-Yong
Hu, Yao-Shi
Meng, Zhong-Yuan
Lu, Chuang-Hong
Xie, Yu-Fei
Yu, Qin
Mai, Lan-Xian
Zeng, Zhi-Yu
-
Funding
Funding for this research was provided by:
Guangxi Zhuang Autonomous Region Health Department (Z-A20240470)
National Natural Science Foundation of China (82070279)
Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention (19-245-34)
Guangxi Clinical Research Center for Cardio Cerebrovascular Diseases (AD17129014)
- License Information
-
More Information
Article History
Received: 18 August 2024
Accepted: 11 December 2024
First Online: 28 December 2024
Declarations
:
: The present study had been approved by Ethics Review Committee of the First Affiliated Hospital of Guangxi Medical University (approval number: 2024-E303-01). The studies involving human participants were reviewed and approved by the institutional review boards of the MIT (Cambridge, MA, United States) and BIDMC (Boston, MA, United States). The institutional review boards of the MIT (Cambridge, Massachusetts) and BIDMC (Boston, Massachusetts) reviewed and approved studies involving human participants. Due to the retrospective nature of the study, the Institutional Review Boards of the Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center waived the need for obtaining informed consent. According to national laws and institutional requirements, this study does not require written informed consent.
: The authors declare no competing interests.
